Sat Kartar Life Limited · NSE:SATKARTAR
Sat Kartar Life — Sat Kartar Shopping — H1FY26 Earnings Presentation
37 slides from Sat Kartar Life's earnings presentation, Oct 30, 2025
Slide 1: Exchange intimation cover letter under Regulation 30
Date: 30.10.2025 To, The Manager Listing Compliance Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai-400051 SYMBOL: SATKARTAR ISIN: INE0NB801022 Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirem
Slide 2: Sat Kartar Shopping Ltd - Investor Presentation H1FY26
Sat Kartar Shopping Ltd Revolutionizing Wellness with Ayurveda Investor Presentation H1FY26
Slide 3: Safe Harbour Statement
Safe Harbour Statement This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sat Kartar Shopping Limited (Sat Kartar, The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Charaka Samhita
THE IMPORTANCE Charak Samhita is an ancient and foundational text in the field of Ayurveda, the traditional system of medicine that originated in India over 3,000 years ago. Attributed to the sage Charaka, the text is one of the earliest and most comprehensive compilations of Ayurvedic knowledge, co
Slide 5: Ayurveda - The Science of Life
Ayurveda The Science of Life
Slide 6: About
About We are more than a brand; we are your partner in a healthier journey, inspired by Ayurveda and backed by science. At Sat Kartar Shopping, we are dedicated to empowering individuals to embrace a healthier, more balanced lifestyle through the timeless wisdom of Ayurveda. As a modern Ayurveda hea
Slide 7: Sat Kartar: A Snapshot
Sat Kartar: A Snapshot 02 03 01 1000+ 32% 39.7% Team Strength Return on Return on Capital Equity (ROE) Employment (ROCE) 10 04 120+ Pan-India SKUs Presence 09 05 Formulations 25,000 08 07 06 approved by Daily Unique Ministry of AYUSH 16+ 1200+ In house Leads Remedial Call Executives R&D Solutions 6
Slide 8: Key Quarterly Highlights
Key Quarterly Highlights Domestic In-House Manufacturing 01 02 Acquisitions The company unveils strategic In-House The company acquired 100% equity share Ayurvedic Capsule Facility, Advancing capital of Ajooni Life Sciences Private Supply Chain Control, Operational Limited and additional 57% equity(
Slide 9: Our Care and Support To Your Problems
Our Care and Support To Your Problems REMEDIES TO 16+ PROBLEMS 80% Revenue Sexual Wellness Diabetes Piles Care De- Addictions Bone & Joints Contribution 20% PCOS Respiratory Hair Liver Infertility Mind Immune Lungs Personal Revenue PCOD Support Care Care Support Care Support Care Care Contribution 8
Slide 10: Healing Across India
Healing Across CE North India : 51% PRESEN South India : 49% R We operate and ensure availability of our OU products all over India We deliver to the parts of the country even where e-commerce fails to deliver Top Revenue contributing states: We serve to more than 11,600 Pincodes across India Tamil
Slide 11: A Team That Speaks Wellness in Every Vernacular Language
The Team Driving Growth Ayurveda First 1200+ Strong Workforce A dedicated focus on Ayurveda makes us a trusted player in the A Team That natural wellness space. Multilingual Reach Speaks Languages: Hindi Multilingual Support Teams Wellness in Kannada We connect with people in their vernacular langua
Slide 12: Sat Kartar Growth Formula
Sat Kartar Growth Formula CASH EFFICIENCY + SCALE = PROFITABLE GROWTH Company's major focus is to be asset light and generate higher cashflows. ASSET-LIGHT MODEL & DATA DRIVEN Grow without heavy assets keeping capital free and margins strong STRONG BRAND LEVERAGING DATABASE POSITIONING & OF 30+MILLI
Slide 13: Our Growth Strategy
Our Growth Strategy In-House Manufacturing & Diversification 50% of Ayurvedic capsules will now be made in-house, ensuring quality control and faster product innovation. Hyper-Personalized Wellness AI-driven recommendations and personalization for an existing database of 30M+ consumers segmented by
Slide 14: Vision 2028: ₹500 Cr Targeted Revenue Aspiration
Way Forward VISION 2028 ₹500 Cr Targeted Revenue Aspiration We're maximizing the value of our unique customer By FY28, we aspire to outpace industry growth by achieving more than 2x database of 30+ Million Consumers by implementing the sector’s growth rate, driven by our operational efficiency, disc
Slide 15: Ajooni Life Sciences In-House Capsule Manufacturing Facility
Ajooni Life Sciences IN-HOUSE CAPSULE MANUFACTURING FACILITY Enhanced Quality Control Ajooni Life Sciences Private Status Reduced dependency on third-party Limited (Wholly-Owned) Successfully Commissioned & quality assurance and better control over Commercial Production Commenced raw materials. Soni
Slide 16: Partnership with Indian Ministry
Partnership with Indian Ministry ANTI-DRUG CAMPAIGNS ACROSS THE COUNTRY ANTICIPATED IMPACT Each event will reach close to 100 individuals in need. Product supply directly supports recovery efforts, increasing the social value of the program. KEY RESPONSIBILITY SECI is a prestigious council under the
Slide 17: Revenue and Marketing Funnel
Revenue and Marketing Funnel Lead Generation & Awareness 01 Attract potential customers through digital and social media marketing, informative campaigns, and leveraging multilingual outreach across platforms such as Google, Meta, and television. Engagement 02 Engage interested leads using vernacula
Slide 18: Keeping the Spirit of Ayurveda Alive
Keeping the Spirit of Ayurveda Alive
Slide 19: Our Journey So Far - From Roots to Reach
Our Journey So Far - From Roots to Reach 2012 2013-2016 2018 2022 2024 2025 Company TV Marketing Digital Marketing Revenue IPO Application Post 1. IPO Launch on NSE Emerge Incorporation Push Initiation Milestone: 50 Revenue milestone 2. Acquired Ajooni Life Crores of 100 Crores Sciences and Plantome
Slide 20: From Research To Delivery: Our Product Journey
From Research To Delivery: Our Product Journey Initial market analysis Medical formulations received Regulatory submission Launching product Final delivery to and insights for evaluation for approval marketing campaigns customers Formulations Formulations developed are Market Marketing of Delivery o
Slide 21: Asset Light Model
Asset Light Model FOCUSING ON ASSET LIGHT BUSINESS MODEL AND HIGHER RETURN RATIOS Strategic Contract Manufacturing Quality Assurance We follow a strategic contract Through robust contracts, we retain manufacturing approach: control over: Partnering with trusted third-party Proprietary Ayurvedic form
Slide 22: From the Promoter's Desk
From the Promoter’s Desk Sat Kartar Shopping Ltd. has delivered an outstanding financial As we look ahead, Sat Kartar is moving decisively toward performance in H1FY26, reaffirming our commitment to profitable growth, international expansion. The integration of our USA subsidiary and operational exc
Slide 23: Meet The Team
Meet The Team Manprit Singh Chadha Pranav Singh Chadha Simrati Kaur Promoter & COO Promoter & Director Promoter & Director Mr. Manprit Singh Chadha is a Pranav brings digital marketing Simrati brings expertise in Chartered Accountant by expertise, specializing in AI- digital marketing, driving end-
Slide 24: Board Of Directors
Board Of Directors Ved Prakash Sanjay Kumar Richa Takkar Managing Director Executive Director Non-Executive Director Steve Austin Pereira Manoj Kumar Verma Sunil Kumar Mehdiratta Independent Director Independent Director Independent Director 23
Slide 25: Bridging Ancient Wisdom With Modern Science
Bridging Ancient Wisdom With modern Science OUR TEAM OF MEDICAL CONSULTANTS Dr. Dipti Jain Dr. Hindika Bhagat Dr. Abhinesh Tiwari Dr. Pooja Verma Dr. Meghna Attray Experience: 22+ Years Experience: 8+ Years Experience: 5+ Years Experience: 5+ Years Experience: 5+ Years Specialization: Liver Speciali
Slide 26: Product Portfolio
Product Portfolio Product Portfolio Specific problem led Lifestyle led Curative niche therapeutic area Areas Addiction Sexual Wellness Piles Immunity Care Diabetes Hair fall Personal Care Bone and Joint pain Mind Care PCOS Respiratory Support PCOD 25
Slide 27: Product Portfolio
Product Portfolio Bones and Joints Provides relief from muscle stiffness Helps reduce excruciating joint pain Instant and long-lasting results No side effects Sexual Wellness Boosts testosterone & increases sperm count. Piles Stimulates the nervous system. Provides stamina and boosts energy. Control
Slide 28: Product Portfolio
Product Portfolio Addiction Suppresses addiction cravings. Purifies and detoxifies blood No withdrawals or relapse symptoms. Strengthens vital organs. Diabetes Stimulates secretion from Pancreatic beta -Cells Others Boosts acceptance of glucose metabolizing hormones. Normalises blood sugar. Fertilit
Slide 29: Vedabay - Where Wellness meets Personalization
VEDABAY Where Wellness meets Personalization
Slide 30: Our Premium Wellness Brand
Our Premium Wellness Brand ~ VENTURING INTO HIGH MARGIN PRODUCT VERTICALS Vedabay Vitili-Go Vedabay Testo Vedabay Safed Musli Vedabay Vedabay Ayush 82 Build Psory Sys Vedabay Vedabay Lungs Vedabay De- Vedabay Liver Detox Stop Piles Glutathione Detox Varicose Tablets 29
Slide 31: Industry Overview
Industry Overview The Science of Life
Slide 32: Industry Overview
Industry Overview India’s Ayurvedic Products Market Size India’s Ayurvedic Wellness Market Size ~ ₹ 3,605 billion 2nd 70%+ 50 Largest AYUSH Global Raw Herbal US$ 42.2 billion % f 16 AGR o Market Globally Material Sourced 40 C India accounts for nearly India is one of the world’s US $ billion 30 80%
Slide 33: Financials
Financials
Slide 34: Standalone Profit & Loss
Standalone Profit & Loss (₹ in Crores) H1FY26 H2FY25 H1FY25 YoY % FY25 FY24 Revenue from Operations 88.35 87.13 75.79 16.57 162.92 127.91 Raw material cost 5.21 4.86 4.14 - 9.00 9.03 Employee Expenses 11.30 13.72 13.74 - 27.60 29.59 Other Expenses 61.57 59.95 52.28 - 112.09 79.05 EBITDA 10.28 8.60 5
Slide 35: Balance Sheet
Balance Sheet (₹ in Crores) Particulars March 2025 March 2024 Equity Capital 16 3 Reserves 36 7 Borrowings 6 2 Other Liabilities 6 11 Total Liabilities 64 22 Fixed Assets 6 3 CWIP 0.28 0 Investments 1 2 Other Assets 56 18 Total Assets 64 22 34
Slide 36: Key Financial Highlights
Key Financial Highlights 162.92 14.23 127.91 10.28 10.24 88.35 75.79 (₹ in Crores) REVENUE 5.63 (₹ in Crores) EBITDA H1FY26 H1FY25 FY25 FY24 H1FY26 H1FY25 FY25 FY24 11.63 8.81 8.73 8.00 EBITDA MARGIN 7.43 6.00 5.04 4.92 PAT MARGIN (%) (%) H1FY26 H1FY25 FY25 FY24 H1FY26 H1FY25 FY25 FY24 35
Slide 37: Get in touch
Get in touch info@satkartar.in AYUSH DIVECHA | DARSHIL PANDYA G12-14, 7th Floor- Commerce Centre, Mumbai- 400034 Email : ir@merlincapital.co.in Contact : +91 81048 55515